Optima Capital’s Biogen BIIB Stock Holding History

Optima Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25	Closed	-$4.4K	–	277
2025 Q4	$4.4K	Buy	+25	New	+$4.08K	﹤0.01%	638

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Optima Capital's BIIB Position: Q1 2026 in Review

Optima Capital sold out of Biogen (BIIB) in Q1 2026, closing a stake of 25 shares — an estimated $4.4K sold.

Optima Capital first reported a position in BIIB in Q4 2025 and held it in 1 quarter. The position peaked at $4.4K in Q4 2025. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Optima Capital reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 25 Biogen shares in Q1 2026, an estimated $4.4K.
Optima Capital first reported a position in Biogen in Q4 2025 and held it in 1 quarter.
Optima Capital's Biogen position peaked at $4.4K in Q4 2025.
1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.